Index 2010 performance summary 18 Medicines 5, 20, 50 Accounting policies 90, 142, 200 Neuroscience 2, 27, 50, 61, 147, 206 Acquisitions 167 Nomination and Governance Committee 111, 112, 115 Annual general meeting 118, 216 Oncology 2, 27, 50, 64, 147, 206 Aptium Oncology, Inc. 75 Operating profit 4, 16, 82, 148 Articles of association 214, 216 Operational overview 4 Astra Tech AB 75 Other investments 144, 157, 159 AstraZeneca PLC financial statements 198 Our marketplace 10 AstraZeneca PLC balance sheet 199 Outsourcing 14, 15, 40, 44, 101 Audit Committee 111, 112, 113 Patents see Intellectual property Biologics 11, 12, 42, 66, 99, 101 Patient safety 44 Board 106 People 15, 16, 18, 36, 46, 173 Branches 117 Pipeline 15, 16, 18, 27, 51, 96, 206 Business background and results overview 81 Political donations 118 Capital and reserves 166 Portfolio Investment Board PIB 116 Capitalisation 86 Post-retirement benets 93, 103, 162 Cardiovascular 2, 27, 50, 52, 147, 206 Pricing 11, 16, 33 Cash and cash equivalents 144, 157 Principal risks and uncertainties 96 Chairmans statement 6 Product revenue information 147 Chief Executive Ofcers review 8 Property, plant and equipment 85, 89, 144, 153 Combined Code 109 Provisions for liabilities and charges 85, 89, 161 Commitments and contingent liabilities 178 Regulatory requirements 12 Company history 211, 216 Related party transactions 213 Competition 12, 99 Relations with shareholders 112 Compliance and Group Internal Audit 116 Remuneration Committee 111, 112, 115, 119, 120 Consolidated statement of cash ows 141 Research and development 9, 12, 26, 92, 143, 148 Consolidated statement of changes in equity 140 Respiratory & Inammation 2, 27, 50, 67, 206 Consolidated statement of comprehensive income 138 Responsible Business 9, 15, 18, 40 Consolidated statement of financial position 139 Rest of World 4, 72, 217 Corporate Responsibility See Responsible Business Restructuring 4, 38, 79, 148 Directors interest in shares 132 Results of operations 2009 87 Directors responsibility statement 136 Results of operations 2010 82 Dividends 6, 86, 117, 167, 213, 214 Safety, health and wellbeing 46 Earnings per ordinary share 4, 151 Sales and marketing 16, 32 Emerging markets 10, 32, 33, 38, 71, 73, 98, 217 Sales by therapy area 50 Employee costs and share options for employees 173 Science Committee 111, 112, 115 Environmental sustainability 45 Segment information 151 Established markets 10, 32, 38, 71, 73, 217 Senior Executive Team SET 108, 116 Ethics including stem cell research 30, 33, 41, 42, 43 Share capital 117, 167, 202, 211 and animal research Share repurchase 4, 6, 7, 86, 87, 117, 167, 202 Executive Directors and Senior Executive Teams 123 Statutory and other information 196 remuneration and terms of employment Strategy 10 Finance income and expense 148 Subsidiaries 117, 197 Financial highlights inside front cover Supply and manufacturing 34 Financial instruments 146, 158 Taxation 85, 89, 90, 93, 103, 143, 149, 195 Financial position 2009 89 Taxation information for shareholders 214 Financial position 2010 85 Trade and other payables 85, 89, 144, 161 Financial risk management 90, 168 Trade and other receivables 85, 89, 144, 157 Form 20-F 115 Trade marks 98, inside back cover Gastrointestinal 2, 27, 50, 56, 147, 206 Transactions with directors 131 Glossary 217 UK corporate governance 109 Goodwill 85, 89, 92, 143, 154 UK Corporate Governance Code 109 Group financial record 204 US 10, 72, 217 Group financial statements 135 US corporate governance 115 Growth drivers 10 Working with others 3 Independent auditors report 137, 198 Infection 2, 27, 50, 58, 147, 206 Case studies Inammation see Respiratory & Inammation Surviving coronary heart disease 13 Intangible assets 85, 89, 92, 143, 155, 178 Taking medicines 19 Intellectual property 14, 30, 97, 98 Managing asthma 23 Interest-bearing loans and borrowings 145, 158, 170, 201 Tackling counterfeit drugs 35 Inventories 89, 144, 157 Searching for new antibiotics 39 Key performance indicators 16, 41, 43 Improving healthcare in Uganda 49 Leases 144, 196 Improving healthcare in China 77 Litigation 92, 98, 101, 102, 145, 178, 200, 203 Personalising cancer treatments 104 Managing risk 95 Market denitions 217 220 Index AstraZeneca Annual Report and Form 20-F Information 2010 Trade marks Trade marks of the AstraZeneca group of companies appear throughout this Annual Report in italics.
AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trade marks of the AstraZeneca group of companies.
Trade marks of companies other than AstraZeneca appear with a sign and include: Abraxane, a trade mark of Abraxis BioScience, LLC.
: Advair Diskus, a trade mark of Glaxo Group Limited: Celebrex, a trade mark of G. D. Searle LLC: Cubicin, a trade mark of Cubist Pharmaceuticals, Inc. : CytoFab, a trade mark of Protherics Inc. : Ethyol, a trade mark of Scherico Ltd in certain countries and AstraZeneca in others: Iscover, a trade mark of Sano-Aventis: Kombiglyze, a trade mark of Bristol-Myers Squibb Company: Lipitor, a trade mark of Pzer Ireland Pharmaceuticals: Onglyza, a trade mark of Bristol-Myers Squibb Company: Plavix, a trade mark of Sano-Aventis: Tearo, a trade mark of Forest Laboratories, Inc. : and Trilipix, a trade mark of Fournier Industrie et Sant.
Designed and produced by Board and portrait photography by Marcus Lyon This product is printed on Heaven 42 paper.
This paper is made from virgin wood bre from well-managed forests independently certied according to the rules of the Forest Stewardship Council FSC.
The mill uses pulps that are totally chlorine free TCF, and some pulp is bleached using an elemental chlorine free ECF process.
The inks in printing this Annual Report are all vegetable-based.
Printed at St Ives Westerham Press Ltd, ISO9001, ISO14001, FSC certied and CarbonNeutral Contact information Registered of ce and corporate Registrar headquarters Equiniti Limited AstraZeneca PLC Aspect House 2 Kingdom Street Spencer Road London W2 6BD Lancing UK West Sussex BN99 6DA Tel: 44 0 20 7604 8000 UK Fax: 44 0 20 7604 8151 Tel freephone in the UK : 0800 389 1580 Investor relations Tel outside the UK : E-mail: ir@astrazeneca.
com 44 0 121 415 7033 UK: as above Swedish Central Securities Depository Sweden: Euroclear Sweden AB AstraZeneca AB PO Box 7822 SE-151 85 Sdertlje SE-103 97 Stockholm Sweden Sweden Tel: 46 0 8 553 260 00 Tel: 46 0 8 402 9000 Fax: 46 0 8 553 290 00 US: US Depositary Investor relations JPMorgan Chase & Co AstraZeneca Pharmaceuticals LP PO Box 64504 1800 Concord Pike St Paul PO Box 15437 MN 55164-0504 Wilmington US fide 19850-5437 Tel toll free in the US : US 800 990 1135 Tel: 1 302 886 3000 Tel outside the US : Fax: 1 302 886 2972 1 651 453 2128 E-mail: jpmorgan.
com Our website This Annual Report is also available on our website, astrazeneca.
